Not exact matches
The new indication puts Kymriah in direct competition with Gilead Sciences» Yescarta, which was
approved by the U.S. Food and Drug Administration in October for
treatment of adults with diffuse large B - cell
lymphoma who have failed to respond to other
treatments.
The U.S. Food and Drug Administration (FDA) is expected to decide by Nov. 29 whether to
approve Kite's CAR T, axi - cel, for
treatment of adults with advanced
lymphoma.
The drug is already
approved in many countries as a
treatment for some forms of leukemia and
lymphoma, under the name Campath.
The therapy is
approved by the U.S. Food and Drug Administration for relapsed or
treatment - resistant Hodgkin
lymphoma, and it is commonly prescribed to patients whose disease has progressed after autologous stem cell transplant, a procedure that replenishes the bone marrow with the patient's own healthy stem cells after therapy.
As an organization of physicians and scientists who care for desperately ill patients, including those with blood cancers such as leukemia,
lymphoma, and myeloma, the American Society of Hematology (ASH) is supportive of efforts to provide insurance parity for all
approved evidence - based cancer
treatments.
The first monoclonal antibody for cancer (rituximab, Rituxan, directed to CD20 on B lymphocytes) is
approved for the
treatment of non-Hodgkin
lymphoma by the FDA.
The FDA has
approved the CAR T - cell therapy axicabtagene ciloleucel (Yescarta) for the
treatment of large B - cell
lymphomas in adults who have failed or relapsed after two or more prior
treatments.
Current
treatment options for patients, aside from watchful waiting, include chemotherapy and rituximab, which was
approved for first - line follicular
lymphoma in 2006.
Brentuximab vedotin was previously
approved by the FDA to treat cHL after relapse, cHL after stem cell transplant when a patient is at a high risk of relapse or progression, systemic anaplastic large cell
lymphoma (ALCL) after failure of other
treatment, and primary cutaneous ALCL after failure of other
treatment.
The US Food and Drug Administration (FDA) recently
approved the oral Bruton tyrosine kinase (BTK) inhibitor ibrutinib for the
treatment of patients with relapsed or refractory marginal zone
lymphoma who require systemic therapy and have had at least one prior anti-CD20 therapy.
The targeted drug brentuximab vedotin (Adcetris ®)-- a monoclonal antibody linked to a chemotherapy drug — is
approved to treat Hodgkin
lymphoma in patients whose disease has failed to respond to other
treatment and, as of August 2015, to prevent relapse following a stem cell transplant.